Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > ORGANIZATION
ORGANIZATION
- No Correlation Between Drowsiness and Efficacy of 2nd-Generation Antihistamine Drugs: HIRS
September 30, 2011
- JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery
September 28, 2011
- JPMA Asks for Continued R&D Tax Credit System
September 26, 2011
- Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
- FY2010 Deficit 2nd-Biggest Ever: Kenporen
September 26, 2011
- Over 95% of Patients Agree to Investigational Use of Removed Tissues: NCC Chief Director Kayama
September 22, 2011
- FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
- Discontinue Re-pricing Following Market Expansion: Mr Umeda of PhRMA
September 19, 2011
- NIBIO Project Making Progress in Discovery of Safety Biomarkers for Evaluating Drug Toxicity
September 19, 2011
- Keizai Doyukai’s Hasegawa Has Not Given Up on 5% Corporate Tax Cut
September 14, 2011
- FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
- Mr Hasegawa of Keizai Doyukai Welcomes Incoming Noda Administration
September 12, 2011
- Sales of Class 1 OTC Drugs Recovering Since January 2010: JSMI
September 12, 2011
- JGA to Prepare Transparency GLs
September 6, 2011
- Gaining Piece of the Pie in Growing Market “Best for Fast Results”: Keizai Doyukai’s Hasegawa
September 6, 2011
- Industry Objects to Proposals that Would Expand Range of Drugs Subject to Re-pricing
September 5, 2011
- FPMAJ Proposes Setting NHI Prices for All Generics at or Above Minimum Statutory Prices
September 5, 2011
- JSGM Calls for Consideration of Generic Makers’ Cost Burden for Applications Based on Data in Public Domain
September 5, 2011
- Legal Prescription Rate Hits Record High 63.1% in FY2010: JPA
September 5, 2011
- 1st Meeting of Asia Cooperation Conference to Be Held Next March
September 5, 2011
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…